Purple Biotech (PPBT) Research & Development (2014 - 2026)
Purple Biotech (PPBT) posted quarterly Research & Development of $1.2 million for Q1 2026, up 61.84% year-over-year from $760000.0 in Q1 2025, and down 32.75% quarter-over-quarter from $1.8 million in Q4 2025.
Purple Biotech (PPBT) Research & Development (2014 - 2026) Analysis & Trends
Purple Biotech (PPBT) has reported Research & Development for 12 consecutive years, with $1.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development rose 61.84% year-over-year to $1.2 million; the TTM figure through Mar 2026 stood at $4.2 million (down 15.29% YoY), while the FY2025 annual figure was $3.7 million, down 51.04% from the prior year.
- Research & Development fell to $1.2 million in Q1 2026 per PPBT's latest filing, from $1.8 million in the prior quarter.
- Across five years, Research & Development topped out at $6.0 million in Q1 2022 and bottomed at $458000.0 in Q4 2024.
- Historically, Research & Development has averaged $2.7 million across 5 years, with a median of $2.4 million in 2024.
- Annual changes were most pronounced in 2024 — Research & Development sank 91.26% — and 2025, when it jumped 299.34%.
- Purple Biotech's Research & Development stood at $4.8 million in 2022, then grew by 8.76% to $5.2 million in 2023, then tumbled by 91.26% to $458000.0 in 2024, then surged by 299.34% to $1.8 million in 2025, then tumbled by 32.75% to $1.2 million in 2026.
- Business Quant data shows PPBT's Research & Development at $1.2 million in Q1 2026, $1.8 million in Q4 2025, and $587000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Purple Biotech | 133.62 | 133.62 | - | 702,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.23 Mn |
| Dec 31, 2025 | 1.83 Mn |
| Sep 30, 2025 | 587,000.00 |
| Jun 30, 2025 | 553,000.00 |
| Mar 31, 2025 | 760,000.00 |
| Dec 31, 2024 | 458,000.00 |
| Sep 30, 2024 | 1.35 Mn |
| Jun 30, 2024 | 2.39 Mn |
| Mar 31, 2024 | 3.42 Mn |
| Dec 31, 2023 | 5.24 Mn |
| Sep 30, 2023 | 4.59 Mn |
| Jun 30, 2023 | 3.71 Mn |
| Mar 31, 2023 | 3.50 Mn |
| Dec 31, 2022 | 4.82 Mn |
| Sep 30, 2022 | 3.47 Mn |
| Jun 30, 2022 | 2.08 Mn |
| Mar 31, 2022 | 5.95 Mn |
| Dec 31, 2021 | 4.87 Mn |
| Sep 30, 2021 | 1.62 Mn |
| Jun 30, 2021 | 2.09 Mn |